- Recruiting
NCT04566328: Phase 3 - Testing the Use of Combination Therapy in NDMM, the EQUATE Trial - EAA181
Updated: Sep 25, 2022
EQUATE TRIAL
EAA181 / EQUATE
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Sponsor
ECOG-ACRIN Cancer Research Group
Collaborator
National Cancer Institute (NCI)
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.
Multiple Locations
ClinicalTrials.gov Identifier: NCT04566328
Official Title: Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
First Posted: September 28, 2020
Click here for details on ClinicalTrials.gov
Click here for details on Cancer.gov
EAA181 / EQUATE Home Page - ECOG-ACRIN Cancer Research Group
Bortezomib : National Cancer Institute
Bortezomib : MedlinePlus Drug Information
Lenalidomide: National Cancer Institute
Lenalidomide: MedlinePlus Drug Information
Dexamethasone : National Cancer Institute
Dexamethasone : MedlinePlus Drug Information
Daratumumab : National Cancer Institute
Daratumumab : MedlinePlus Drug Information
Daratumumab and Hyaluronidase-fihj Injection: National Cancer Institute
Daratumumab and Hyaluronidase-fihj Injection: MedlinePlus Drug Information
- National Cancer Institute NCI
* Bortezomib (Velcade)
* Lenalidomide (Revlimid)
* Dexamethasone (Decadron)
* Daratumumab (Darzalex)
Locations
United States, Alaska
United States, Arizona
United States, Arkansas
United States, California
United States, Colorado
United States, Connecticut
United States, Delaware
United States, Florida
United States, Idaho
United States, Illinois
United States, Indiana
United States, Iowa
United States, Kansas
United States, Kentucky
United States, Louisiana
United States, Maryland
United States, Massachusetts
United States, Michigan
United States, Minnesota
United States, Missouri
United States, Montana
United States, Nebraska
United States, New Mexico
United States, New York
United States, North Carolina
United States, North Dakota
United States, Ohio
United States, Oklahoma
United States, Oregon
United States, Pennsylvania
United States, Rhode Island
United States, South Carolina
United States, South Dakota
United States, Texas
United States, Utah
United States, Virginia
United States, Washington
United States, Wisconsin
United States, Wyoming
Other ECOG Trials
NCT04566328: Phase 3 - EAA181 / EQUATE - Testing the Use of Combination Therapy in NDMM
NCT03937635: Phase 3 - EAA173 / DETER-SMM - Lenalidomide, Dex +/- Daratumumab in High-Risk Smoldering Myeloma
NCT03941860: Phase 3 - EAA171 / OPTIMUM - Addition of Ixazomib to Lenalidomide in Patients With Residual Myeloma
NCT02465060: Phase 2 - EAY131 / NCI-MATCH - Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Related Posts
NCT03710603: Phase 3 (Perseus) EMN17 - Dara-VRd Vs VRd - Daratumumab, VELCADE, Len, Dex VS VELCADE, Len, Dex in NDMM
NCT03652064: Phase 3 (CEPHEUS) MMY3019 - Dara-VRd Vs VRd - Bortezomib, Lenalidomide, Dex and +/- Daratumumab - NDMM
NCT02195479: Phase 3 (ALCYONE) Dara-VMP Vs VMP - Bortezomib, Melphalan, Prednisone & Daratumumab
NCT02541383: Phase 3 (CASSIOPEIA) Dara-VTd Vs VTd - Bortezomib, thalidomide, dex +/-Daratumumab before & after ASCT
NCT02874742: Phase 2 (GRIFFIN) - Dara-VRd Vs VRd - Daratumumab, Len., Bortezomib & Dex in NDMM
NCT04268498: Phase2 (ADVANCE) Dara-KRd - Daratumumab, Carfilzomib, Lenalidomide, Dex NDMM Multiple Myeloma
NCT03290950: Phase 2 (Manhattan) Dara-KRd - A Study of Daratumumab in Patients With NDMM wKRd-D
NCT02252172: Phase 3 (MAIA) Dara-Rd Vs Rd - Dara, Lena & Dex VS Len & Dex in previously untreated Myeloma
NCT03729804: Phase 3 (COBRA) - KRd Vs VRd in Patients with Newly Diagnosed Multiple Myeloma
NCT04096066: Phase 3 KRd Vs Rd - A Trial That Compare Two Treatments TIE - NDMM
NCT01402284: Phase 2 - KRd - Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients